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Overexpression of Glucocorticoid-
induced Leucine Zipper (GILZ) 
increases susceptibility to 
Imiquimod-induced psoriasis and 
involves cutaneous activation of 
TGF-β1
Elena Carceller1,*, Marlies Ballegeer2,3,*, Julie Deckers2,3,4,5, Carlo Riccardi6, Stefano Bruscoli6, 
Tino Hochepied2,3, Claude Libert2,3,† & Paloma Pérez1,†
Psoriasis vulgaris is a chronic inflammatory skin disease affecting millions of people. Its 
pathophysiology is complex and involves a skin compartment with epidermal and immune cells 
which produce cytokines, e.g. belonging to the IL-23–Th17-cell axis. Glucocorticoids (GCs) are the 
most common therapeutics used in cutaneous inflammatory disorders and GC-induced leucine zipper 
(GILZ) has emerged as a mediator of GCs due to its anti-inflammatory actions, theoretically lacking 
GC side-effects. We evaluated whether GILZ may provide a better therapeutic index in comparison to 
GCs during the onset and progression of psoriasis by generating and characterizing a mouse model 
with generalized overexpression of this protein (GILZ-Tg mice) and the imiquimod (IMQ) psoriasis 
model. Unexpectedly, in GILZ-Tg mice, the severity of IMQ-induced psoriasis-like skin lesions as well as 
induction of cytokines commonly up-regulated in human psoriasis (Il-17, Il-22, Il-23, Il-6, S100a8/a9, 
and Stat3) was significantly more pronounced relative to GILZ-Wt mice. The increased susceptibility to 
IMQ-induced psoriasis of GILZ-Tg mice was significantly associated with skin-specific over-activation 
of TGF-β1-mediated signaling via SMAD2/3. Our findings demonstrate that GILZ may behave as pro-
inflammatory protein in certain tissues and that, similar to prolonged GC therapy, GILZ as an alternative 
treatment for psoriasis may also have adverse effects.
Psoriasis vulgaris is a chronic relapsing inflammatory skin disease which affects 2–3% of the population and 
is characterized by demarcated red scaly skin lesions most often on the elbows, knees, hands and feet. The dis-
ease is characterized by hyperproliferation and abnormal differentiation of the epidermis along with infiltration 
of immune cells, mainly T cells and dendritic cells. Immune cells secrete high amounts of pro-inflammatory 
cytokines, which in turn induce production of additional cytokines by keratinocytes and other cutaneous cells1. 
In particular, T helper 17 (Th17) cells, activated and maintained by IL-23, secrete IL-17, IL-22 and TNFα , con-
stituting the so-called IL-23–Th17-cell axis, which plays a major role in several diseases including psoriasis2–4.
The etiology of the disease is complex and includes defects in genes associated with the epidermal barrier 
(Lce3 family members), NF-κ B activation (Rel, Nfkbia, Tnfaip3), and adaptive immune responses (Il-23r, Il-12b), 
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as well as alterations in different signaling pathways, as shown by studies in human patients and in mouse mod-
els5,6. In transgenic mice, keratinocyte-targeted overexpression of STAT3 and transforming growth factor-beta1 
(TGF-β 1) or combined deletion of JUN and JUNB in this cell type induces a pathology closely mimicking pso-
riatic skin7–9.
Synthetic GCs form the most common treatment for numerous cutaneous inflammatory and immune dis-
eases including psoriasis, because of their anti-inflammatory potential10,11. However, the chronic use of GCs for 
treating psoriasis is compromised by adverse effects (skin atrophy, telangiectasia, and potential systemic detri-
mental actions), necessitating the search for more specific downstream mediators of GC action. GCs bind and 
activate the GC-receptor (GR) that acts as a ligand-dependent transcription factor, binding to hormone response 
elements or GREs at the regulatory sequences of its target genes, a process classically referred to as transactiva-
tion12,13. GR can also regulate gene expression by interfering with other transcription factors (e.g., NF-κ B and 
AP-1) without direct binding to DNA (a process referred to as transrepression). It is currently accepted that both 
mechanisms of GR are required to achieve optimal anti-inflammatory GC effects12.
In the past few years, several anti-inflammatory mediators induced through GRE-dependent transcription, 
such as GC-induced leucine zipper (GILZ), have received increasing attention13–15. GILZ, which is encoded by the 
Tsc22d3 gene, was originally described by the Riccardi laboratory as a dexamethasone-responsive gene in the thy-
mus16 and is currently known to be ubiquitously expressed. The mouse and human Tsc22d3 genes are highly sim-
ilar at the nucleotide level (more than 90%) and encode a leucine zipper protein that modulates several signaling 
pathways, crucial to inflammation and immune response, including NF-κ B and RAS/RAF/MAPK. GC-induced 
transcriptional up-regulation of GILZ interferes with NF-κ B activation through direct interaction of GILZ with 
the p65 NF-κ B protein, resulting in inhibition of NF-κ B nuclear translocation, DNA binding, and transactiva-
tion17,18. In fact, GILZ has emerged as a possible alternative to GC therapies, due to its anti-inflammatory actions 
which are not accompanied by GC adverse effects, as demonstrated by several mouse models of inflammation and 
immune dysfunction14,19–22. High GILZ protein levels, by GILZ-overexpressing transgenic mice or by injection of 
TAT-GILZ fusion proteins, have shown to lead to diminished inflammatory responses in experimentally induced 
colitis. The effect was similar to dexamethasone, as quantitated by reduced pro-inflammatory Th1 cytokines, 
IFN-γ , and TNF-α 23. Also, TAT-GILZ protected mice against LPS-induced endotoxemia24. An immunomodula-
tory GILZ-derived peptide ameliorated experimentally autoimmune encephalomyelitis18 and more recently it was 
reported that deficiency of GILZ in mice resulted in augmented inflammation after IMQ treatment, demonstrat-
ing that GILZ plays a T-cell intrinsic role limiting pathogenic Th17 responses in the context of psoriasis25. It must 
thus be concluded that in most experimental settings, GILZ appears as a key modulator of regulatory T cells, and 
constitutes a major mechanism of GC-mediated immunosuppression14,22,26,27.
We have previously reported that Tsc22d3 is transcriptionally up-regulated during the differentiation of kerat-
inocytes in vitro28; however, the role of GILZ in skin pathophysiology is largely unknown. Here, we aimed to eval-
uate the consequences of GILZ overexpression during the onset and progression of psoriasis by generating and 
characterizing a mouse model with generalized overexpression of this protein (GILZ-Tg mice). We describe the 
generation of these mice. Furthermore, we used the well-validated imiquimod (IMQ)-induced model of psoriasis 
in which psoriatic inflammation is induced by repetitive topical application of Aldara® , a cream containing 5% 
of the toll-like receptor 7 (TLR7)-agonist IMQ29,30. The phenotype of IMQ-treated mouse skin closely resembles 
the histological and molecular changes associated to human psoriasis, in particular the activation of the IL-23–
Th17-cell axis. The key evidence supporting that IMQ treatment in mice is a relevant model for studying human 
psoriasis is that the clinical use of Aldara® for treating cutaneous keratosis, superficial basal cell carcinoma and 
warts produces local reddening and inflammation in all treated patients29–32.
Results
Generation of mice overexpressing GILZ. Using a Gateway-compatible ROSA26 locus targeting vec-
tor33, we generated conditional GILZ-Tg overexpressing mice by knocking in the mouse Tsc22d3/Gilz-1 cDNA 
preceded by a loxP flanked stop cassette under control of the ROSA26 promoter (Fig. 1a). Mice homozygous 
for the loxP flanked stop cassette and one allele of Nestin-cre, expressing Cre in all cell types, especially in the 
brain, testis and gut and to a lesser extent in the liver34, were generated by crossing. These mice were used in all 
the experiments and are designated as GILZ-Tg mice. Because of some degree of leakiness of the loxP flanked 
stop cassette, we used mice without the cassette, but with the same genetic background as the GILZ-Tg mice as 
controls (GILZ-Wt). The GILZ-Tg mice were viable and showed relative increases of expression of the transgene 
in a tissue-dependent manner ranging between 3- and 6-fold (Fig. 1b and data not shown). We also detected a 
significant increase of GILZ at the protein level in various tissues including spleen and bone marrow-derived 
macrophages (Fig. 1c). In adult skin, the overexpression of GILZ at the mRNA and protein level ranged between 
3- and 8-fold and did not cause any obvious histopathological changes in tissue architecture (Fig. 1b,c and Fig. S1).
GILZ overexpression increases IMQ-induced psoriasis-like skin lesions. To investigate the role of 
GILZ overexpression in the IMQ model, we topically treated GILZ-Tg and GILZ-Wt mice with Aldara® or con-
trol cream for 7d29,30 (Fig. 2). Erythema (redness) and scaling were scored daily. We found that the response to 
IMQ was more pronounced in GILZ-Tg relative to GILZ-Wt mice with marked increases in skin alterations from 
day 4 onwards and significant differences in scaling at d7 (Fig. 2a, approximately 4-fold). Representative images 
of the increased skin erythema (asterisks) and severe desquamation (arrows) after 7d of IMQ treatment in the 
GILZ-Tg mice are shown (Fig. 2b).
The histopathology of IMQ-treated mouse skin is characterized by epidermal thickening, abnormal epidermal 
differentiation and neutrophil infiltration (Munro-like abscess), which closely resemble the human histological 
picture of the disease1,6,29. IMQ treatment resulted in epidermal thickening in both GILZ-Wt and GILZ-Tg mice 
relative to untreated animals (Fig. 2c, H&E; brackets), with greater increased epidermal width in IMQ-treated 
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GILZ-Tg mice. Scaling of the skin often reflects abnormal keratinocyte differentiation with retention of the nuclei 
in the stratum corneum, the outer most layer of the epidermis (parakeratosis). Consistent with the augmented 
scaling in IMQ-treated GILZ-Tg mice (Fig. 2a), we also detected overall increased parakeratosis (Fig. 2c, H&E; 
thick arrows). In addition, we also detected the presence of cell infiltrates just beneath the stratum corneum 
(Fig. 2c, H&E; arrowhead), highly similar to Munro-like abscesses in psoriasis skin lesions.
We assessed the expression of keratin (K)6, which is normally restricted to hair follicles but becomes 
up-regulated in diseased skin35. Immunostaining showed hyperproliferative epidermis positive for K6 in both 
GILZ-Wt and GILZ-Tg mice (Fig. 2c, K6). The expression of loricrin was confined to the upper differentiated 
layers of the epidermis in GILZ-Wt while this marker was focally absent in GILZ-Tg mice correlating with aug-
mented parakeratosis36 (Fig. 2c, LOR; thick arrows).
One possible mechanism by which nuclei accumulate in the stratum corneum is by impaired expression and/or 
function of Caspase-14 (CASP-14), a unique non-apoptotic epidermal-specific caspase that is crucial for a func-
tional skin barrier as it mediates the proteolytic processing of pro-filaggrin to make granules of the epidermal 
granular layer37,38. In GILZ-Wt skin, CASP-14 was detected in the more differentiated epidermal layers while 
it was absent in GILZ-Tg skin, correlating with parakeratotic areas (Fig. 2c, CASP-14; arrows and thick arrows, 
respectively).
Figure 1. Generation and phenotyping of mice overexpressing GILZ (GILZ-Tg mice). (a) Scheme of the 
transgene construct. Restriction enzyme sites and the location of the 5′ probe used for Southern blot analysis 
are depicted. The ROSA26 locus was targeted by homologous recombination using the targeting vector (top). At 
the end, the ROSA26 locus was modified (bottom). (b) Relative mRNA levels of Tsc22d3/Gilz1 in the indicated 
tissues were assessed by RT-QPCR. Mean values ± SD are shown; asterisks denote statistically significant 
differences relative to controls (Student’s t test; n = 4 per genotype; *p < 0.05; ***p < 0.001). (c) Representative 
Western blot showing GILZ protein levels in the spleen, bone marrow-derived macrophages, and skin of 
GILZ-Wt and GILZ-Tg mice. Tubulin is shown as a loading control. Quantitation of Western blot shows mean 
values ± SD; asterisks denote statistically significant differences relative to controls (Student’s t test; n = 3 per 
genotype; *p < 0.05; ***p < 0.001).
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Besides these epidermal alterations, psoriasis is characterized by pronounced inflammatory infiltrates mainly 
consisting of T cells and dendritic cells. Upon IMQ treatment, the dermal cellularity was clearly increased in 
GILZ-Tg mice relative to GILZ-Wt mice (Fig. 2c, compare dermal infiltrates). Note that the endogenous Tsc22d3 
mRNA levels decreased by approximately 60% in IMQ-treated GILZ-Wt skin (Fig. 2d), in agreement with the 
previously reported Tsc22d3 down-regulation in various inflammatory settings14. In contrast, Tsc22d3 mRNA 
levels remained high before and after the IMQ treatment in GILZ-Tg skin (Fig. 2d).
Augmented susceptibility of GILZ-Tg mice to IMQ-induced psoriasis is not due to increased cir-
culating inflammatory cytokines. It has been demonstrated that besides the cutaneous phenotype, top-
ical IMQ induced systemic effects including increased circulating cytokines and splenomegaly29,30,32. Consistent 
with these published data, we detected an increase in the relative spleen/body ratio in control mice and this sple-
nomegaly was further increased in GILZ-Tg mice (Fig. 2e, 2-fold vs 3-fold induction, respectively).
We also assessed the serum levels of IL-17A, IL-17F, and TNFα in GILZ-Tg and GILZ-Wt mice treated 
with IMQ for 0, 2, 4, and 7 d. In control mice, and according to our previous reports32 all these cytokines were 
induced by IMQ (2–7-fold) with a peak of expression at 2–4 d after treatment (Fig. 3). The levels of these circu-
lating cytokines increased to a similar extent in GILZ-Tg mice although with small variations in the kinetics of 
Figure 2. GILZ-Tg mice show increased psoriatic features in response to imiquimod (IMQ). (a) Score 
of the erythema and scaling in GILZ-Wt and GILZ-Tg for the duration of the experiment. V: vehicle; IMQ, 
imiquimod. (b) Macroscopical appearance of GILZ-Wt and GILZ-Tg mice treated with IMQ at day 7.  
(c) Representative Hematoxilin&Eosin (H&E) stained and immunohistochemistry sections of adult mouse 
skin of IMQ-treated GILZ-Wt and GILZ-Tg mice. Epidermal thickening (brackets), hyperkeratosis (asterisks), 
abnormal differentiation with parakeratosis (thick arrows), and epidermal infiltrate (Munro-like abscess, 
arrowhead) are indicated. Immunostaining with keratin (K)6, Loricrin (LOR), and Caspase-14 (CASP-14) 
antibodies is also shown. Note the increased dermal cellularity in IMQ-treated GILZ-Tg relative to GILZ-Wt 
mice. Bar: 50 μ m. Samples from two independent experiments were assessed (n = 15 GILZ-Wt, n = 16 
GILZ-Tg). (d) Relative Tsc22d3/Gilz mRNA levels in GILZ-Wt and GILZ-Tg mouse skin were assessed by RT-
QPCR before and after treatment with IMQ at day 7. (e) Splenomegaly was determined by the weight ratio of 
spleen relative to body. (d,e) Mean values ± SD are shown. Post hoc Tukey test #p < 0.05; ***p < 0.001, n = at 
least 5 per genotype and treatment. Asterisks: significance between treatments within each genotype; hashes: 
significance between genotypes in the same treatment group.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:38825 | DOI: 10.1038/srep38825
induction (Fig. 3). These data suggest that the augmented susceptibility of GILZ-Tg mice to IMQ-induced psori-
asis is due to differences in the cutaneous response rather than differences in the systemic response.
Increased up-regulation of Th17-dependent cytokines in GILZ-Tg mouse skin. Next, we assessed 
the cutaneous relative mRNA levels of several cytokines of the IL-23–Th17 axis as well as other inflammatory 
markers known to be up-regulated in human and mouse psoriatic skin6,30. We detected significant up-regulation 
of Il-17f and Il-22 mRNA levels (2.5- and 4-fold, respectively) and a trend of Il-23 induction (although it did not 
reach significance) in IMQ-treated vs untreated GILZ-Wt skin (Fig. 4a). The lack of consistent Il-23 up-regulation 
was likely due to kinetics and/or individual variability. Importantly, all these cytokines were significantly more 
up-regulated in lesioned GILZ-Tg skin relative to controls (Fig. 4a, 4- to 12-fold). The calcium-binding proteins 
S100A8/A9 are the most up-regulated proteins in lesional psoriatic skin, and are expressed in keratinocytes and 
immune cells such as neutrophils39. IL6 and STAT3 are also induced in human patients and mouse models of pso-
riasis1. We detected statistically significant increases of S100a8, S100a9, and Stat3 in IMQ-treated GILZ-Wt mice 
and notably, the levels of these markers as well as Il6 were further augmented in GILZ-Tg treated mice (Fig. 4b,c; 
1.5- to 5-fold higher than in Gilz-Wt). Our data thus show that transgenic mice overexpressing GILZ treated with 
IMQ exhibit increased psoriasiform-like features by histological and molecular criteria.
In IMQ-treated GILZ-Tg mice, the pro-inflammatory actions of overexpressed GILZ occur specif-
ically in skin but not in other tissues. We wondered whether GILZ overexpression was pro-inflammatory 
in other tissues after topical IMQ treatment as several organs are also affected by this protocol including the 
spleen29 (Fig. 2e) and the intestine, recently claimed as an important amplifying organ in the IMQ model29,32. We 
thus collected the spleen and intestines of GILZ-Wt and GILZ-Tg mice before and after IMQ treatment to assess 
the expression of Th-17 dependent cytokines.
Figure 3. Augmented susceptibility of GILZ-Tg mice to IMQ-induced psoriasis is not due to increased 
circulating inflammatory cytokines. Serum levels of circulating cytokines IL-17A, IL-17F, and TNFα were 
assessed in GILZ-Tg and GILZ-Wt mice treated with IMQ for 0, 2, 4, and 7 d. Mean values ± SD are shown. 
Post hoc Tukey test **p < 0.01; ***p < 0.001; n = at least 3 per genotype and treatment. Asterisks: significance 
between treatments within each genotype; no statistical significance was detected between genotypes in the 
same treatment group.
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In the gut of transgenic mice, the relative mRNA levels of Il-17f, Il-22, and Il-23 after IMQ treatment were 
either down-regulated or unchanged relative to IMQ-treated controls (Fig. 4d–f). However, in the spleen, Il-17f 
and Il-6 mRNA levels by IMQ showed an increased trend of up-regulation in transgenics relative to controls 
although without statistical significance (Fig. 4g–i); in this tissue, Il-23 mRNA levels showed no change among 
treatments or genotypes.
These data demonstrate that the cytokine profile in the skin of IMQ-treated GILZ-Tg mice was different to 
that of intestine or spleen and suggests that in this disease model, GILZ may act as pro-inflammatory specifically 
in the skin.
IMQ-induced psoriasis in GILZ-Tg mice involves cutaneous activation of TGF-β1/SMAD2/3. It 
has been reported that GILZ enhances TGF-β 1 signaling by binding to and promoting SMAD2/3 phosphoryla-
tion and activation of FoxP3 expression26. Also, mice overexpressing TGF-β 1 in keratinocytes developed pheno-
types and molecular alterations similar to human psoriasis, via a SMAD2/3-dependent mechanism7,40. To assess 
whether GILZ overexpression correlates with an augmented TGF-β 1-mediated signaling, we determined the 
expression of total and phosphorylated (p)-SMAD2/3. Our data show constitutive increase of active SMAD2/3 
ratio in GILZ-Tg relative to GILZ-Wt untreated skin as well as an augmented SMAD2/3 activation after IMQ 
treatment (Fig. 5a,b; left panels). Consistent with these findings, we detected p-SMAD2/3 in the skin of untreated 
and IMQ-treated GILZ-Tg mice by immunolocalization (Fig. 5c). It is worth noting that p-SMAD2/3 was found 
in the epidermal and dermal compartments although its activation in IMQ-treated GILZ-Tg mice was more 
robust in epidermal keratinocytes.
Importantly, activation of TGF-β 1 signaling occurred specifically in skin but not in gut or spleen of GILZ-Tg 
and GILZ-Wt mice (Fig. 5a,b; middle and right panels). We also assessed possible changes in Tgfb1 mRNA levels 
in skin and spleen but found no differences among treatments or genotypes (Fig. S2), suggesting that GILZ over-
expression alters TGF-β 1 activity but not its expression levels.
Figure 4. Increased up-regulation of inflammatory mediators in IMQ-treated GILZ-Tg relative to 
GILZ-Wt mouse skin. Relative mRNA levels of the indicated genes were assessed by RT-QPCR in skin (a–c), 
gut (d–f), and spleen (g–i) collected from the same individuals after IMQ treatment (7d). Mean values ± SD are 
shown. Post hoc Tukey test *, #p < 0.05; **, ##p < 0.01; ***, ###p < 0.001; n = at least 5 per genotype and treatment. 
Asterisks: significance between treatments within each genotype; hashes: significance between genotypes in the 
same treatment group.
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Contribution of immune cells and keratinocytes to the increased psoriasiform features in 
GILZ-Tg mice. We next tried to assess whether the more severe psoriasis-like phenotype found in 
IMQ-treated GILZ-Tg mice was due to the contribution of skin infiltrating immune cells, keratinocytes, or 
both. As an initial approach, we assessed the composition of the immune infiltrates in the skin of GILZ-Tg and 
GILZ-Wt mice treated with vehicle or IMQ for 7 d by FACS analysis. Despite minor differences, there were no 
significant changes in the neutrophil, dendritic cells, or T cell populations among genotypes (Fig. S3).
We then examined more directly whether immune cells and keratinocytes showed a differential response to 
inflammation in vitro. First, we isolated lymph nodes from GILZ-Tg and GILZ-Wt mice that had been treated 
with cream or IMQ for 7 d, re-stimulated the cells with IMQ for 3 d, and checked IL-17A in the supernatant 
(Fig. 6a). We detected a significant but similar induction of IL-17A in both control and GILZ-Tg cells (5- and 
5.5-fold, respectively) indicating that IMQ induces the Th17-mediated response in lymph nodes equally in both 
genotypes (Fig. 6a).
We also assessed the effects of IL-17A on the expression of the psoriatic marker S100a8 in cultured kerat-
inocytes that were transiently transfected with either an empty vector or GILZ cDNA containing plasmid. 
Importantly, both basal and IL-17A-induced S100a8 mRNA levels were significantly higher (approximately 30%) 
in GILZ-transfected keratinocytes relative to controls (Fig. 6b). Collectively, these data indicate that despite IMQ 
triggers a similar enhanced Th17-mediated response in immune cells from control and GILZ-Tg mice, it results 
in higher induction of the marker of psoriasis S100a8 in GILZ overexpressing keratinocytes (Fig. 6).
Discussion
The generation and characterization of a mouse model with generalized overexpression of GILZ allowed us to 
demonstrate that although GILZ is considered an anti-inflammatory therapeutic protein in different experimen-
tal models, GILZ-Tg mice showed increased susceptibility to IMQ-induced psoriasis by histological and molec-
ular criteria.
The score of skin lesions showed significant differences in scaling but not in erythema in GILZ-Tg relative 
to GILZ-Wt mice at d7 (Fig. 2a). However, there was a tendency towards increased erythema in GILZ-Tg vs 
GILZ-WT mice from d4 onwards, which was not statistically significant likely due to masking of the reddening 
by the severe desquamation in GILZ-Tg mice (Fig. 2a,b).
The histopathology of IMQ-treated GILZ-Tg mouse skin also featured more pronounced epidermal thicken-
ing, parakeratosis, and neutrophil infiltration relative to controls (Fig. 2). Importantly, we found that the severe 
parakeratosis in GILZ-Tg mice correlated with the absence of CASP-14, a caspase whose proteolytic role is 
required for normal epidermal differentiation and that is usually confined to the upper epidermal layers (Fig. 2c). 
Figure 5. TGF-β1 signaling mediator SMAD2/SMAD3 is overactivated by IMQ treatment in GILZ-Tg 
mouse skin but not in other tissues. Representative immunoblotting showing the expression of total and 
phospho(p)-SMAD2/3 in skin (left panels), gut (middle panels), and spleen (right panels) collected from the 
same individuals (GILZ-Wt and GILZ-Tg) before and after IMQ treatment (7d). Actin is shown as a loading 
control. (b) Quantitation of immunoblotting shows mean values ± SD; asterisks denote statistically significant 
differences relative to controls (Student’s t test; n = 31; *p < 0.05). (c) Immunostaining with p-SMAD2/3 
antibody demonstrates induction of the TGF-β 1 signaling pathway in the epidermis and dermis of IMQ-treated 
GILZ-Tg and GILZ-Wt mice. Bar: 50 μ m. (a–c) Samples from two independent experiments were assessed 
(n = 15 GILZ-Wt, n = 16 GILZ-Tg).
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However, the lack of CASP-14 is not likely to cause the development of parakeratotic plaques but rather contrib-
ute to the formation of a defective barrier and, thus, to the aggravation of psoriatic lesions, as CASP-14 knock-out 
mice did not show spontaneous parakeratosis38 but developed increased parakeratosis after IMQ treatment40. 
How GILZ modulates CASP-14 is currently unknown but given its restricted expression to differentiating kerat-
inocytes, it is plausible that the observed CASP-14 down-regulation in GILZ-Tg skin reflects alterations in other 
transcription factors regulating epidermal differentiation38. Also, the focal absence of CASP-14 in GILZ-Tg skin 
lesions is consistent with previous work reporting that CASP-14 was reduced in lesional psoriatic skin likely 
due to the action of T-helper type 2 cytokines38,41,42. It is currently unknown whether the increased action of 
Th17-dependent cytokines in GILZ-Tg mouse skin also plays a causative role in down-regulating CASP-14 
function.
One major question is whether these severe psoriasis-like features in GILZ-Tg mice are due to systemic and/
or cutaneous local responses to IMQ. According to previous reports32, our data showed increased production of 
circulating cytokines after IMQ treatment but there were no differences among genotypes (Fig. 3) ruling out that 
a differential systemic response contributes to the severity of the GILZ-Tg skin lesions.
It is also plausible that both skin infiltrating immune cells and keratinocytes may contribute to the more severe 
cutaneous phenotype of IMQ-treated GILZ-Tg mice. Our data showed no major differences in the composition of 
skin neutrophil or T cell infiltrates of GILZ-Tg and GILZ-Wt mice nor in the response of isolated lymphoid cells 
to IMQ (Figs S3 and 6a). However, we demonstrated that the overexpression of GILZ in cultured keratinocytes 
induced a significantly enhanced up-regulation in the mRNA levels of the psoriatic marker S100a8 in response to 
IL-17A (Fig. 6b). Overall, our data indicate that the pro-inflammatory actions of GILZ are specific to the skin as 
neither the intestine nor spleen showed increased levels of Th17-dependent cytokines relative to controls (Fig. 4). 
Also, these pro-inflammatory effects of GILZ seem to be enhanced in keratinocytes in a cell-type-specific manner 
likely contributing to the increased psoriasiform features in GILZ-Tg mice.
Given that Tsc22d3 was strongly down-regulated in IMQ-treated GILZ-Wt but not in GILZ-Tg skin (Fig. 2d), 
it is also possible to speculate that GILZ down-regulation is required for resolution of the inflammation and that 
the continuous expression of GILZ in transgenic skin exerts paradoxical pro-inflammatory actions. Importantly, 
it was previously reported that Tsc22d3 was also down-regulated by 2.6-fold in the skin of psoriatic lesions vs 
non-lesional matched biopsies43. Thus, it is feasible that the observed pro-inflammatory effects are the conse-
quence of high levels of exogenous GILZ instead of physiological levels, indicating that GILZ activity must be 
tightly controlled for skin homeostasis.
It is also important that in this model, the pathological actions of GILZ correlated with skin-specific TGF-β 
1/SMAD2/3 activation (Fig. 5). Thus, caution is required when considering the use of GILZ as an alternative 
treatment for psoriasis since high doses and/or long treatments may also have adverse effects. It is tempting to 
hypothesize that the observed insensitivity and/or resistance of a subset of psoriatic patients treated with GCs 
may be due to GILZ overexpression eventually leading to increased p-SMAD2/3, which would result in aggrava-
tion of skin lesions.
Our results are seemingly contradictory to the fact that GILZ-deficient mice treated with IMQ exhibited 
increased Th17-mediated inflammation25. Importantly, untreated GILZ-deficient mice already showed sponta-
neously increased production of IL-17 and IL-22 by lymph node cells in vivo25. While these results demonstrate 
a key role for GILZ in regulating Th-17 dependent cytokines by T cells and dendritic cells, it is unclear whether 
this basal inflammation contributes to the increased susceptibility of GILZ-deficient mice to IMQ. In contrast, in 
Figure 6. GILZ overexpression in keratinocytes correlates with a significant enhanced response to IL-17A. 
(a) Brachial lymph nodes were isolated from either vehicle- or IMQ-treated GILZ-Tg and GILZ-Wt mice (n = 3 
mice per genotype and treatment) after 7d. Cells were then re-stimulated with vehicle or IMQ for 3 d, and IL-
17A levels were measured in the supernatant. (b) Cultured keratinocytes were transfected with either an empty 
vector or GILZ cDNA containing plasmid and the expression of S100a8. mRNA levels was assessed after IL-
17A treatment (100 ng/ml) for 24 h. n = at least 6 independent replicates per transfection and treatment. Mean 
values ± SD are shown. Post hoc Tukey test #p < 0.05; ##p < 0.01; ***p < 0.001. Asterisks: significance between 
treatments within each genotype; hashes: significance between genotypes in the same treatment group.
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the absence of treatment, GILZ-Tg and GILZ-Wt mouse skin exhibited similar expression of these cytokines with 
significant increases occurring only in response to IMQ (Fig. 4a). Also, we have characterized the skin alterations 
of mice overexpressing GILZ after IMQ treatment while the report by Morand and colleagues did not specifically 
address the epidermal phenotype25. The apparent discrepancies between the KO results and our results highlight 
that the use of complementary approaches such as GILZ-deficient vs GILZ-Tg mice may be necessary to provide a 
full understanding of the true biology behind a protein. Taken together the results of the gain and loss of function 
models indicate that GILZ levels must be tightly regulated to effectively reduce inflammation, with too much or 
too little having pathological consequences.
Materials and Methods
Animals. Generation of GILZ transgenic mice. The generation of GILZ-Tg mice is described in the Results 
section. The construct contained the mouse Tsc22d3/Gilz-1 cDNA preceded by a loxP flanked stop cassette under 
control of the ROSA26 promoter, and followed by an IRES-EGFP cDNA. After identifying correctly targeted 
embryonic stem cell clones by Southern blotting, chimeric mice that transmitted the transgene to their offspring 
were generated. The experimental mice were homozygous for the transgenic construct and had one Nestin-cre 
allele and are designated as GILZ-Tg mice. As controls, we used mice without the cassette (GILZ-Wt), but with 
exactly the same genetic background (C57BL/6).
Mice were maintained at 12 light/12 dark cycle, caged in groups (4–6 per cage) under SPF conditions, and 
having access to ad libitum food and water. All the animal protocols were approved by the ethical committee of 
the Faculty of Sciences at Ghent University, and followed the European guidelines and regulations.
Imiquimod-induced psoriasis-like skin lesions. Female GILZ-Wt and GILZ-Tg mice (8–12 weeks) were used 
for the IMQ-induced psoriasis mouse model. Two days after shaving, Aldara® (5% IMQ, 3 M Pharmaceuticals; 
62.5 mg) or control cream (Ava, Fagron NV) was topically applied on mouse dorsal skin daily for 7 consecutive 
days. Macroscopic parameters such as skin erythema and scaling were daily scored independently on a scale from 
0 to 4: 0, none; 1, slight; 2, moderate; 3, marked; 4, very marked. On day 7, a section of dorsal skin and gut was col-
lected, snap-frozen and stored at − 80 °C until use or fixed in 70% ethanol for histopathological analysis. Spleens 
were collected and weight was expressed relative to mouse body weight. The total number of animals used was 31 
(15 GILZ-Wt, 16 GILZ-Tg; two independent experiments).
Antibodies. Polyclonal antibodies against pSMAD2/3 Ser 465/467 (3108 P), SMAD2 (5339 P), and SMAD3 
(9523 P) were from Cell Signaling Technology, Inc. Actin (A2066, Sigma-Aldrich, St. Louis, MO) was used as 
protein loading control. Secondary peroxidase-conjugated anti-rabbit antibodies were from GE HealthCare. The 
GILZ antibody was purchased from eBioscience (14-4033).
For immunostaining, rabbit polyclonal antibodies against K6 (PRB-169P) and loricrin (PRB-145P) were from 
Covance, Berkeley, CA, and Caspase-14 (sc-5628) and p-SMAD2/3 (sc-11769-R) were from Santa Cruz, CA. 
Secondary biotin-conjugated anti-rabbit or anti-mouse antibodies (Jackson ImmunoResearch, West Grove, PA) 
were used.
Histology and immunohistochemistry analysis. Mouse dorsal skins (n = 15 GILZ-Wt, n = 16 GILZ-Tg) were 
dissected and fixed in 70% ethanol for two days, then in paraffin. 4-μ m thick sections were used for hematox-
ylin/eosin (H&E) staining and immunohistochemical analysis. After incubation with primary and secondary 
biotin-conjugated antibodies immunoreactivity was revealed using the ABC kit Vectastain (PK-6100; Vector 
Labs) and the sections were counterstained with hematoxylin. All skin samples were evaluated for histopatho-
logical analysis.
RNA isolation and quantitative RT-PCR. Total RNA was isolated from mouse dorsal skin using Trizol (Life 
Technologies). After RNA isolation, DNase treatment of the samples was done according to the manufacturer’s 
instructions (Thermo Scientific). Subsequently, samples were reverse transcribed to make cDNA using RevertAid 
H Minus Reverse Transcriptase and using oligo dT primers (Thermo Scientific). Quantitative real-time PCR was 
performed using specific primers and FastStart Universal SYBR Green Master ROX (Roche) on Applied Biosystems 
7500 Fast real time PCR machine. Hprt1, Ubc and Rpl were used as housekeeping genes. At least four to five bio-
logical replicates were used per genotype and treatment. The sequences of primers used are as follows: Hprt1 
(Forward: 5′ -AGTGTTGGATACAGGCCAGAC-3′ , Reverse: 5′ -CGTGATTCAAATCCCTGAAGT-3′ ), Ubc 
(Forward: 5′ -AGGTCAAACAGGAAGACAGACGTA-3′ , Reverse: 5′ -TCACACCCAAGAACAAGCACA-3′ ), 
Rpl (Forward: 5′ -CCTGCTGCTCTCAAGGTT-3′ , Reverse: 5′ -TGGTTGTCACTGCCTCGTACTT-3′ ), S100a8 
(Forward: 5′ -AAATCACCATGCCCTCTACAAG-3′ , Reverse: 5′ -CCCACTTTTATCACCATCGCAA-3′ ), S100a9 
(Forward: 5′ -ATACTCTAGGAAGGAAGGACACC-3′ , Reverse: 5′ -TCCATGATGTCATTTATGAGGGC-3′ ), 
Il-17f (Forward: 5′ -CCCAGGGCTGTTCTAATTCCTT-3′ , Reverse: 5′ -GACACAGGTGCAGCCACCTTT-3′ ), 
Stat3 (Forward: 5′ -AGCTGGACACACGCTACCT-3′ , Reverse: 5′ -AGGAATCGGCTATATTGCTGGT-3′ ), Il-22 
(Forward: 5′ -TCAGTGCTAAGGATCAGTGCT-3′ , Reverse: 5′ -TGATTGCTGAGTTTGGTCAGG-3′ ), Il-23a 
(Forward: 5′ - AAAATAATGTGCCCCGTATCCAG-3′ , Reverse: 5′ - GCTCCCCTTTGAAGATGTCAG-3′ ), 
Il-6 (Forward: 5′ - TAGTCCTTCCTACCCCAATTTCC-3′ , Reverse: 5′ - TTGGTCCTTAGCCACTCCTTC-3′ ), 
Tsc22d3/Gilz1 (Forward: 5′ - CGGTCTATCAGCTGCACAATTT-3′ , Reverse: 5′ - ACATCCCCTCCAAGCA 
GAGA-3′ ).
Western blotting. Whole-cell protein extracts from mouse dorsal skin and cultured keratinocytes were prepared 
as previously described44. Samples were boiled in Laemmli buffer, separated on 10% SDS-PAGE, and transferred 
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onto nitrocellulose membranes (Hybond ECL, GE Healthcare). Gel loading control was done by Ponceau S stain-
ing on the membranes after transfer. Membranes were blocked and incubated with specific polyclonal primary 
antibodies followed by incubation with peroxidase-conjugated anti-rabbit secondary antibodies. The immuno-
reactive bands were analyzed using ECL2 (Thermo Scientific) with the ImageQuant 4000 Biomolecular Imager 
(GE Healthcare). Protein band density was determined using Image J software. Experiments were performed with 
a minimum of three biological replicates.
Determination of serum cytokine levels. Serum samples were assayed for IL-17A, IL-17F, and TNFα using 
Luminex technology (BioPlex, Bio-Rad) in accordance with the manufacturer’s protocol.
Isolation of lymph nodes, treatments, and determination of IL-17A levels. Ear-draining (brachial) lymph nodes 
were isolated at d7 from GILZ-Tg and GILZ-Wt mice treated with Aldara or vehicle (Ava cream). Lymph nodes 
were minced through a 70 μ m cell strainer (BD Falcon) to obtain single cell suspensions which were re-stimulated 
with 10 μ g/ml Aldara or vehicle for 3 d. Cells were cultured in RPMI-1640L medium supplemented with 
Glutamax, 10% fetal calf serum, gentamycin and β -mercaptoethanol (Gibco; Life Technologies) IL-17A cytokine 
production was measured in the supernatant of cultured cells using Luminex technology (BioPlex; Bio-Rad) in 
accordance with the manufacturer’s protocol.
Keratinocyte cells, transfection and treatments. Keratinocytes were isolated from 8-week-old C57BL6/DBA 
female mouse dorsal skin and immortal keratinocyte cell lines were generated and cultured as previously 
described28. Keratinocytes were seeded in a 6-well plate to a confluence of about 80% 24 h prior to transfection. 
Empty expression vector cassette pCDNA4 was used as a negative control. Keratinocytes were transiently trans-
fected with pEGFP-C1-Gilz1 plasmid (500 ng) using Lipofectamine 2000 Reagent (Invitrogen) according to the 
manufacturer’s protocol. Five hours after transfection, medium was replaced and cells were treated with recombi-
nant human IL-17A (R&D Systems) at a concentration of 100 ng/ml for 24 h.
Statistical Analysis. Experimental data were analyzed using Microsoft Excel and IBM SPSS Statistics 23 software. 
In all graphs, data are expressed as the mean value ± SD. When statistical analysis was performed with relative 
values, data were first subjected to logarithmic transformation. Prior to parametric testing, the Levene’s test was 
used to determine whether samples within groups had equal variance. For comparisons between two experimen-
tal groups, we used the Student’s unpaired two-tailed t-test. For comparisons among more than two experimental 
groups, we used the one-way ANOVA which if statistically significant was followed by a post hoc Tukey multiple 
comparison test. P values less than 0.05 were considered statistically significant.
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